Golden State Equity Partners Acquires 2,410 Shares of Novo Nordisk A/S (NYSE:NVO)

Golden State Equity Partners lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 327.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,146 shares of the company’s stock after acquiring an additional 2,410 shares during the period. Golden State Equity Partners’ holdings in Novo Nordisk A/S were worth $271,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of NVO. International Assets Investment Management LLC boosted its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S in the third quarter valued at about $98,765,000. DAVENPORT & Co LLC raised its holdings in shares of Novo Nordisk A/S by 75.1% in the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after buying an additional 451,641 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S in the third quarter valued at about $42,017,000. Finally, World Investment Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after buying an additional 270,234 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $82.64 on Tuesday. The firm’s 50 day moving average is $93.56 and its 200-day moving average is $112.87. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $370.85 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.